Imatinib mesylate has anti-inflammatory properties ... A group of mice were treated with either 33 mg/kg or 100 mg/kg imatinib (which produced blood levels similar to a mid-range dose in humans ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of cancers including chronic myeloid leukemia. In their study, however, Kerkelä et al. report that this drug can be ...

Nilotinib in imatinib mesylate-resistant or intolerant accelerated chronic myeloid leukemia. A Phase II trial was designed to characterize the efficacy and safety of nilotinib (400 mg twice daily ...